A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Erythematosus, Systemic
Lupus Nephritis

Interventions

DRUG: CC-97540
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company